Sobi receives positive CHMP opinion for Kineret® for treatment of rare disease CAPS

Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that the Committee for
Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
has adopted a positive opinion for the use of Kineret for the treatment of
patients with Cryopyrin-Associated Periodic Syndromes (CAPS).

The opinion is based on a positive benefit risk assessment of the results from a
long-term treatment study in children and adults with NOMID/CINCA, the most
severe form of CAPS.

"We look forward to final decision from the European Commission in the coming
months", said Birgitte Volck, Senior Vice President and Chief Medical Officer
for Sobi. "CAPS is a group of rare inherited inflammatory disorders with
symptoms involving fever, rash, joint and muscle pain, fatigue and eye
manifestations which in the more severe cases are potentially life threatening."

"If approved, Kineret will increase treatment flexibility and opportunities to
tailor therapy to patients' individual needs, including initiation of early
treatment", said PD Dr med Jasmin Kümmerle-Deschner at the Universitätsklinikum
Tübingen in Germany.

In December 2012, Kineret became the first and only FDA-approved therapy for
NOMID/CINCA. Sobi will provide Kineret for home treatment in a prefilled syringe
with a graduated label to allow flexible dosing in children.

---

About CAPS
Cryopyrin associated periodic syndromes (CAPS) are a group of rare inherited
autoinflammatory diseases caused by autosomal dominant mutations in a gene
called NLRP3. CAPS is characterized by uncontrolled overproduction of IL-1beta.
IL-1 induces a number of inflammatory responses such as fever, pain
sensitization, bone and cartilage destruction and acute plasma protein
responses. In the most severe form of CAPS, called Neonatal-Onset Multisystem
Inflammatory Disease (NOMID) or Chronic Infantile Neurologic Cutaneous and
Arthritis syndrome (CINCA), it is associated with increased mortality and fever,
rash, chronic aseptic meningitis, sensorineural hearing loss, craniofacial
abnormalities, and bone lesions. When of intermediate severity, called Muckle-
Wells Syndrome (MWS), the disease is typically associated with episodic, intense
and enduring flares and morbidity, including progressive hearing loss and kidney
failure secondary to amyloidosis (a condition where amyloid proteins are
deposited in organs and/or tissues). The mildest form, called Familial Cold
Autoinflammatory Syndrome (FCAS), presents with cold-induced episodes of fever,
rash and malaise. The incidence of CAPS is estimated to be 1:1,000,000
worldwide.

About Kineret (anakinra)
Kineret is a recombinant protein drug approved for, and the reduction in signs
and symptoms and slowing the progression of structural damage in moderately to
severely active rheumatoid arthritis (RA) in combination with methotrexate, in
patients 18 years of age or older who have had an inadequate response to
methotrexate alone. Kineret blocks the biological activity of IL-1 by binding to
the interleukin-1 type 1 receptor, expressed in a wide variety of tissues and
organs. IL-1 is a key mediator of inflammation and driver of autoinflammatory
diseases. For more information on Kineret see the Prescribing Information.
(www.kineretrx.com)

In early 2013, Sobi announced that the US Food and Drug Administration (FDA) had
approved Kineret for the treatment of children and adults with neonatal-onset
multisystem inflammatory disease (NOMID), the most severe form of CAPS. Kineret
thereby became the first and only FDA-approved therapy for NOMID (CAPS).

About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on inflammation and genetic diseases, with three late stage biological
development projects within haemophilia and neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi is
a pioneer in biotechnology with world-class capabilities in protein biochemistry
and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion
(€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com.

For more information - not for publication

 Media relations           Investor relations

 Oskar Bosson, Head of     Jörgen Winroth, Vice President, Head of Investor
 Communications            Relations

 T: +46 70 410 71 80       T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135

 oskar.bosson@sobi.com     jorgen.winroth@sobi.com